Context: There is limited data to characterize treatment patterns of biologics for severe asthma across regions.

Aims: Describe biologic treatment patterns within a severe asthma population across 3 geographical regions.

Methods: Descriptive analysis of treatment patterns of biologics for asthma were conducted using US Optum Clinformatics® Data-Mart database (2017-2021), JMDC database-Japan (2017-2021), and Evidera LiveTracker® from Europe (Germany, France, Italy, Spain, UK), with a retrospective chart review (1992-2022).

Results: A total of 4502, 778, and 1753 patients treated with biologics for asthma was identified in the US, Japan, and Europe, respectively. Anti-IL-5 was the most prescribed biologic: 43% (US), 39% (Japan) and 48% (EU); followed by anti-IgE in the US (31%) and EU (37%), and anti-IL-4/13 in Japan (33%). Switches from index biologic to a 2^nd line biologic were infrequent. Any discontinuation from index biologic for aIL-5 was 63% (US), 28% (Japan) and 3% (EU), aIgE was 70% (US), 50% (Japan) and 10% (EU), aIL-4/13 was 81% (US), 45% (Japan) and 5% (EU).

Conclusions: Differences between biologic treatment patterns across biologics and regions regarding initiation, switches, and discontinuation of therapy for patients with severe asthma were observed.

Funding: GSK: 218238, 219355, 214680